The objective of the present study was to compare the effects of imidapril hydrochloride, an angiotensin converting enzyme inhibitor, and dilazep hydrochloride, an antiplatelet agent, on urinary protein excretion and renal function in patients with chronic glomerulonephritis.
etiology in at least fifty percent of the cases.
1 ) The efficacy of angiotensin converting enzyme (ACE) inhibitors in the treatment of these diseases has recently been demonstrated. [2] [3] [4] In Japan, although the administration of ACE inhibitors for the treatment of chronic renal diseases has become increasingly common, there still exist regional discrepancies in the frequency of their actual use, and this fact might be one of the reasons for the regional differences in the incidence of ESRD. 5) Imidapril hydrochloride is a long-acting ACE inhibitor with no sulfhydryl group whose renoprotective effects, including reduction of proteinuria, have been demonstrated in Dahl rats 6) and in rats given NOS inhibitors. 7) Furthermore, in clinical trials conducted in Japan, imidapril has been shown to significantly decrease microalbuminuria in patients with insulin dependent diabetes mellitus. 8) The clinical efficacy of imidapril in CGN patients, however, has not been fully evaluated. Moreover, ACE inhibitor treatment is not considered to be an appropriate therapy for CGN in Japan and as such is not covered by the national health insurance program. On the other hand, antiplatelet agents have been used in the treatment of renal diseases for many years since long before the advent of ACE inhibitors. Among the antiplatelet agents available, dilazep hydrochloride has been reported to reduce proteinuria in IgA and diabetic nephropathies. [9] [10] [11] According to these reports, dilazep was approved for administration to proteinuric patients, including those with IgA nephropathy in Japan. In this study, the effects of imidapril and dilazep on proteinuria, renal function, and blood pressure in CGN patients were compared.
METHODS
CGN patients with overt proteinuria excretion accompanied by serum creatinine (Cr) concentrations under 2 mg/dL were enrolled in the study (n = 23, 18 men and 5 women, 23 -66 years old). Diagnosis was established based on renal biopsy findings or general laboratory data. In 19 out of the 23 patients, the diagnosis was confirmed by histopathological examination of renal biopsy specimens. In the remaining 4 patients, renal biopsy was not performed either because of old age (over 50 years) or an elevated serum creatinine level (over 1.5 mg/dL). All patients had proteinuria greater than 0.5 g/g Cr, and none had any other diseases such as marked hypertension, diabetes, collagen diseases, or infectious diseases that could account for the proteinuria. The patients were divided into an imidapril group (n = 11) and a dilazep (n = 12) group according to their baseline blood pressure because imidapril administration was approved for only hypertensive patients.
Vol 46 No 4 Imidapril was started at an oral dose of 2.5 mg once a day and increased to 5 mg, as required. Dilazep was administered orally at a daily dose of 300 or 450 mg divided into three equal doses of 100 or 150 mg. Both groups were treated with the corresponding drug for 36 months. The patients were allowed to take their usual medications without any changes during the study period.
Blood pressure, serum creatinine, blood urea nitrogen, total protein, albumin, and total cholesterol levels were measured at the start of the administration and every 6 months thereafter during the study period. Urine was collected for 24 hours prior to each examination, a portion of which was used for the measurement of urinary protein and creatinine concentration. These parameters were measured with an automated analyzer. Blood pressure was measured using a mercury sphygmomanometer with the patient in the sitting position.
This open-label study was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided informed consent after receiving a detailed explanation of the study. Statistical analyses: All data are expressed as the mean value ± SD. Statistical comparisons were made by analysis of variance followed by the Student-Neumann-Keuls test. Evaluation of correlation was determined by the least square method. A value of P < 0.05 was considered statistically significant.
RESULTS

Patient characteristics:
The pretrial characteristics of the two groups are shown in Table I . With respect to the etiology of CGN, 7 patients in the imidapril group and 8 in the dilazep group had IgA nephropathy. There were no significant differences in any of the other characteristics, such as body weight or concomitant medications, between the two groups. However, both SBP and DBP were significantly higher in the imidapril group (Table II) . The imidapril group had slightly more proteinuria, although a statistically significant difference was not found between the two groups. There was no sig- nificant difference in serum creatinine concentration, while the serum BUN level was significantly higher in the imidapril group (Table II) . The average dose of imidapril administered at 36 months was 4.0 ± 1.3 mg/ day and that of dilazep 325.0 ± 58.4 mg/day. Effects on blood pressure reduction (Figure 1 ): In the imidapril group, the average SBP and DBP at baseline were 139.6 ± 17.4 mmHg and 93.6 ± 8.7 mmHg, respectively. Significant reductions in SBP and DBP started to be observed at six months; they stabilized at 123.6 ± 11.0 mmHg and 83.1 ± 6.3 mmHg during the study period and were 122.7 ± 10.5 mmHg and 81.8 ± 9.9 mmHg, respectively, at the end of the study.
In the dilazep group, there was no significant change in SBP (120.0 ± 18.6 mmHg at 36 months). DBP increased gradually to 72.8 ± 13.5 mmHg at 36 months. Although the difference was significant in comparison to the prestudy level, it remained within the normal range. Changes in urinary protein excretion : The reductions in urinary protein excretion adjusted by urinary creatinine are shown in Figure 2 . In the imidapril group, a significant reduction by about 1 g/g Cr was found in the second month of treat- ment; at 6 months and later, when blood pressure had already stabilized, urinary protein excretion continued to decrease gradually. Proteinuria decreased from the prestudy level of 2.16 ± 1.57 g/g Cr to 0.90 ± 0.53 g/g Cr at 36 months. In the dilazep group, urinary protein decreased from 1.15 ± 0.99 g/g Cr at the start of administration to 1.00 ± 0.81 g/g Cr at 36 months. The coefficient of correlation between the decrease in blood pressure and that of proteinuria was determined in the imidapril group from their rates of change at 6 and 36 months. There was no correlation at these time points between the rate of reduction in proteinuria and that of SBP or DBP (%∆ proteinuria versus %∆SBP: r = 0.429, P = NS at 6 months; r = 0.050, P = NS at 36 months), suggesting that the proteinuria-reducing effects of imidapril did not depend on a reduction of blood pressure. Effects on renal function: In the imidapril group, serum creatinine and BUN concentrations were 1.27 ± 0.30 mg/dL and 18.8 ± 3.9 mg/dL at the start of administration and 1.34 ± 0.30 mg/dL and 21.3 ± 5.5 mg/dL at 36 months, respectively. There was no significant change in either parameter. No significant change in serum creatinine or BUN was observed in the dilazep group either. As shown in Figure 3 , while the serum protein and albumin concentrations gradually increased in the imidapril group, there were no changes in the dilazep group. A marked reduction in total cholesterol concentration was also seen in the imidapril group, but not in the dilazep group. Side effects and other abnormal laboratory data: No side effects or other abnormal laboratory data were observed in either group. It should be noted that no adverse effects such as acute deterioration of renal function, hyperkalemia, symptoms associated with hypotension, or dry cough were observed as a consequence of the imidapril administration.
DISCUSSION
In the present study, imidapril was administered for 36 months to patients with overt proteinuria and hypertension, and its effects on proteinuria were investigated. The results demonstrated that in the imidapril group blood pressure stabilized at a lower level and that proteinuria decreased continuously during treatment. Since no correlation was found between the degree of reduction in proteinuria and blood pressure, this proteinuria-reducing effect seemed to be independent of the extent of blood pressure reduction. ACE inhibitors owe much of their proteinuria-reducing action to their effects on glomerular hemodynamics, dilating efferent arterioles greater than afferent arterioles, and thus lowering intraglomerular pressure.
12) It is also reported that ACE inhibitors improve glomerular basement membrane charge and size barriers, as well as endothelial function of the renal vasculature, and inhibit cellular proliferation and extracellular matrix production in the mesangium. Such actions may contribute to the decrease of proteinuria observed during the long-term administration of imidapril. The results of the present study suggest that imidapril can be used for long periods in hypertensives with overt proteinuria and that it probably exerts renoprotective effects. In this regard, our findings are compatible with the results of past largescale clinical trials involving patients with renal dysfunction, especially with diabetic nephropathy. 2, 3) Recently, the fact that proteinuria itself exerts deleterious effects on the progression of renal dysfunction has become a focus of much attention. It is well recognized that in patients with severe proteinuria, renal function deteriorates rapidly. 13, 14) On the other hand, it has also been reported that by decreasing proteinuria the process of glomerular filtration rate (GFR) reduction can be retarded. It has been demonstrated that mechanical and biochemical stress are inflicted on renal tissue when serum-originated protein is filtrated in the glomeruli and reabsorbed along the proximal tubules. 15, 16) Proteinuria is, accordingly, not only an index of pathogenic activity in the glomeruli, but it also contributes directly to the progression of renal dysfunction. Therefore, it is important to reduce the level of proteinuria as much as possible. Imidapril reduced proteinuria by 1 g/g Cr in CGN patients. It has been shown that for each gram of proteinuria reduced per day the GFR decline was slowed by about 1.0 to 2.0 mL/min per year. 17, 18) However, we observed no difference in renal function during the three years of treatment with imidapril compared with the dilazep group, whose proteinuria was not reduced by the drug. The reason for this lack of difference in renal function is not clear, however, a longer follow-up period will presumably make a difference considering that patients in the dilazep group had relatively good baseline renal function. The fact that patients in the dilazep group had an obviously lower baseline blood pressure, and consequently were likely to have better renal function and less proteinuria, may also have been one of the confounding factors.
It has been reported that dilazep significantly reduces urinary protein or albumin excretion in patients with IgA nephropathy, 9) early-stage diabetic nephropathy 10, 11) and normotensive autosomal dominant polycystic kidney disease. 19) Yoshida, et al 20) analyzed the relation between a reduction in proteinuria and renal histological findings in 46 patients with IgA nephropathy administered dilazep. In 18 patients whose proteinuria was reduced by more than 25%, the degrees of glomerular sclerosis, crescent formation, mesangial matrix, and tubulo-interstitial lesions were milder compared with those who had a persistently high proteinuria. IgA or IgG depositions in the glomeruli were also milder in the group responsive to the treatment. In the present study, proteinuria decreased by more than 25% in about 15% of the patients in the dilazep group. There might have been a relatively large number of patients in this group whose renal histopathological status was more advanced than could be estimated from their blood pressure, serum creatinine concentration, and proteinuria. Furthermore, it has been shown that dilazep decreases the release of lipopolysaccharide from cul- Imidapril decreased proteinuria by half, while this effect was not observed with dilazep. Although it is sometimes difficult to evaluate proteinuria in outpatients, the degree of reduction achieved by imidapril was substantial and not simply due to errors associated with urine storage or measurements. In fact, significant increases in serum total protein and albumin concentrations support this point. The marked serum total cholesterol reduction obtained only in the imidapril group without the use of cholesterol-lowering drugs is presumably an effect mediated by a reduction in proteinuria. Conclusions: In summary, imidapril reduced proteinuria during three years of treatment and was useful for the maintenance of renal function. Dilazep also helped to maintain renal function without reducing proteinuria. Further studies conducted on larger numbers of patients for longer durations will be required in the future.
